최근 임상·제약 데이터가 갱신된 96개 프로그램입니다. 변경 이력이 아닌 최신 갱신 순서입니다.
FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer · FRα (folate receptor alpha)
HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer · TROP2
Locally advanced or metastatic urothelial carcinoma · Nectin-4
Metastatic triple-negative breast cancer, pretreated HR+/HER2− breast cancer · TROP2
HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma · HER2
NSCLC (Stage III consolidation), SCLC, biliary tract, HCC · PD-L1
NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1
Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1
Type 2 diabetes, chronic weight management · GLP-1 / GIP receptor
Type 2 diabetes, chronic weight management, CV risk reduction (T2D) · GLP-1 receptor
Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) · PCSK9 (siRNA)
Hyperlipidemia, ASCVD, HeFH · PCSK9
Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH · PCSK9
High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)
Sickle cell disease with recurrent vaso-occlusive events · βA-T87Q-globin (lentiviral)
Sickle cell disease with recurrent VOCs; transfusion-dependent β-thalassemia · BCL11A enhancer (CRISPR/Cas9) → HbF
Severe hemophilia A in adults · Factor VIII (AAV5)
Duchenne muscular dystrophy (DMD) — ambulatory / label-expanded populations · Micro-dystrophin (AAVrh74)
Hemophilia B (congenital Factor IX deficiency) in adults · Factor IX (AAV5 Padua)
Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations · RPE65 (AAV2)
2 / 5 페이지
구조모아 (StructureMoa)항암 chemical structure spider web
KRMediMoa한의학·한약재 임상·근거 데이터
다음 갱신 D-5 · 마지막 9월 2일 · 방문 918 / 70,752